Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages

Immunology and Cell Biology

Volumn 91, Issue 7, 2013, Pages 451-460

  Chaudhuri, Amitabha ^a,b   Wilson, Nicholas S ^a,c   Yang, Becky ^a   Paler Martinez, Andres ^a   Liu, Jinfeng ^a   Zhu, Catherine ^a   Bricker, Nicole ^a   Couto, Suzana ^a   Modrusan, Zora ^a   French, Dorothy ^a   Cupp, James ^a   Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

^b SCIGENOM LABS PVT LTD   (India)

^c EMD Serono Research and Development Institute Inc   (United States)

Author keywords

interferon; macrophage; RON; TLR4

Indexed keywords

INTERFERON; PROTEIN TYROSINE KINASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

METAZOA; MUS; RODENTIA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENESIS; CELL MOVEMENT; FIBROSARCOMA; GENOTYPE; HEPATOCYTE GROWTH FACTOR; INTERFERON TYPE I; MACROPHAGES, PERITONEAL; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PAPILLOMA; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SKIN NEOPLASMS; TH1-TH2 BALANCE; TOLL-LIKE RECEPTOR 4; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME;

EID: 84881474744     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.27     Document Type: Article

References (80)

1. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv Immunol 2011; 109: 87-124.
2. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826. (Pubitemid 47598622)
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
4. Cassady AI, Luchin A, Ostrowski MC, Hume DA. Regulation of the murine TRACP gene promoter. J Bone Miner Res 2003; 18: 1901-1904. (Pubitemid 37322571)
5. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 2003; 101: 1155-1163. (Pubitemid 36139391)
6. Wells CA, Ravasi T, Faulkner GJ, Carninci P, Okazaki Y, Hayashizaki Y et al. Genetic control of the innate immune response. BMC Immunol 2003; 4: 5.
7. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
8. Haber DA, Settleman J. Cancer: drivers and passengers. Nature 2007; 446: 145-146. (Pubitemid 46398653)
9. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-265.
10. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
11. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998; 16: 2927-2933. (Pubitemid 28383277)
12. Iwama A, Wang MH, Yamaguchi N, Ohno N, Okano K, Sudo T et al. Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating protein. Blood 1995; 86: 3394-3403.
13. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000; 261: 229-238.
14. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 2007; 213: 402-411. (Pubitemid 350206512)
15. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008; 100: 1-33. (Pubitemid 351942429)
16. Leonard EJ, Skeel AH. Enhancement of spreading, phagocytosis and chemotaxis by macrophage stimulating protein (MSP). Adv Exp Med Biol 1979; 121B: 181-194.
17. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol 2004; 172: 1825-1832. (Pubitemid 38116831)
18. Morrison AC, Correll PH. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol 2002; 168: 853-860. (Pubitemid 34049588)
19. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011; 11: 807-822.
20. Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 2001; 108: 567-576. (Pubitemid 32777736)
21. Chen YQ, Fisher JH, Wang MH. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J Immunol 1998; 161: 4950-4959. (Pubitemid 28492076)
22. Sharda DR, Yu S, Ray M, Squadrito ML, De Palma M, Wynn TA et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol 2011; 187: 2181-2192.
23. Kline JN, Cowden JD, Hunninghake GW, Schutte BC, Watt JL, Wohlford-Lenane CL et al. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med 1999; 160: 297-303. (Pubitemid 29326103)
24. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191. (Pubitemid 30394990)
25. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-2088. (Pubitemid 29001265)
26. Gruenheid S, Gros P. Forward genetic dissection of innate response to infection in inbred mouse strains: selected success stories. Clin Exp Immunol 2010; 162: 393-401.
27. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010; 29: 243-248.
28. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
29. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
30. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266. (Pubitemid 43121975)
31. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
32. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173. (Pubitemid 30408793)
33. Wei X, Ni S, Correll PH. Uncoupling ligand-dependent and-independent mechanisms for mitogen-activated protein kinase activation by the murine Ron receptor tyrosine kinase. J Biol Chem 2005; 280: 35098-35107. (Pubitemid 41532696)
34. Ni S, Zhao C, Feng GS, Paulson RF, Correll PH. A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol 2007; 27: 3708-3715. (Pubitemid 46726178)
35. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801. (Pubitemid 43261452)
36. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. Cytokine 2010; 49: 237-244.
37. Thomas KE, Galligan CL, Newman RD, Fish EN, Vogel SN. Contribution of interferonbeta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J Biol Chem 2006; 281: 31119-31130. (Pubitemid 44582166)
38. Hashimoto S, Morohoshi K, Suzuki T, Matsushima K. Lipopolysaccharide- inducible gene expression profile in human monocytes. Scand J Infect Dis 2003; 35: 619-627. (Pubitemid 37336883)
39. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121: 1108-1111.
40. Azuma YT, Matsuo Y, Nakajima H, Yancopoulos GD, Valenzuela DM, Murphy AJ et al. Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection. J Pharmacol Sci 2011; 115: 105-111.
41. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000; 59 (Suppl 1), i60-i64.
42. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 2005; 106: 3114-3122. (Pubitemid 41565908)
43. Ripoll VM, Kadioglu A, Cox R, Hume DA, Denny P. Macrophages from BALB/c and CBA/Ca mice differ in their cellular responses to Streptococcus pneumoniae. J Leukoc Biol 2010; 87: 735-741.
44. Lipoldova M, Demant P. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat Rev Genet 2006; 7: 294-305.
45. Demant P. Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. Nat Rev Genet 2003; 4: 721-734. (Pubitemid 37046139)
46. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008; 105: 652-656. (Pubitemid 351171763)
47. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
48. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-729. (Pubitemid 41716746)
49. Kemp CJ. Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 2005; 15: 460-473. (Pubitemid 41318046)
50. Chan EL, Peace BE, Collins MH, Toney-Earley K, Waltz SE. Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 2005; 24: 479-488. (Pubitemid 40188595)
51. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-271.
52. Havelkova H, Badalova J, Svobodova M, Vojtikova J, Kurey I, Vladimirov V et al. Genetics of susceptibility to leishmaniasis in mice: four novel loci and functional heterogeneity of gene effects. Genes Immun 2006; 7: 220-233.
53. Quan L, Stassen AP, Ruivenkamp CA, van Wezel T, Fijneman RJ, Hutson A et al. Most lung and colon cancer susceptibility genes are pair-wise linked in mice, humans and rats. PLoS One 2011; 6: e14727.
54. Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S et al. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. J Biol Chem 2011; 286: 32762-32774.
55. Thobe MN, Gray JK, Gurusamy D, Paluch AM, Wagh PK, Pathrose P et al. The Ron receptor promotes prostate tumor growth in the TRAMP mouse model. Oncogene 2011; 30: 4990-4998.
56. Correll PH, Iwama A, Tondat S, Mayrhofer G, Suda T, Bernstein A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct 1997; 1: 69-83.
57. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
58. Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004; 172: 3059-3069. (Pubitemid 38263695)
59. Vazquez-Torres A, Vallance BA, Bergman MA, Finlay BB, Cookson BT, Jones-Carson J et al. Toll-like receptor 4 dependence of innate and adaptive immunity to Salmonella: importance of the Kupffer cell network. J Immunol 2004; 172: 6202-6208. (Pubitemid 38621226)
60. Liu C, Gao F, Li B, Mitchel RE, Liu X, Lin J et al. TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21. Leukemia 2011; 25: 1516-1519.
61. Naseemuddin M, Iqbal A, Nasti TH, Ghandhi JL, Kapadia AD, Yusuf N. Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int J Cancer 2012; 130: 765-774.
62. Bhattacharya D, Yusuf N. Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012; 2012: 716564.
63. Liu QP, Fruit K, Ward J, Correll PH. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol 1999; 163: 6606-6613.
64. Ray M, Yu S, Sharda DR, Wilson CB, Liu Q, Kaushal N et al. Inhibition of TLR4-induced IkappaB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein. J Immunol 2010; 185: 7309-7316.
65. Stuart WD, Kulkarni RM, Gray JK, Vasiliauskas J, Leonis MA, Waltz SE. Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology 2011; 53: 1618-1628.
66. Nikolaidis NM, Gray JK, Gurusamy D, Fox W, Stuart WD, Huber N et al. Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam 17 production. Shock 2010; 33: 197-204.
67. Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC et al. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001; 69: 1477-1482. (Pubitemid 32187597)
68. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-848. (Pubitemid 44631652)
69. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgammaand lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (Pubitemid 32391043)
70. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207: 2053-2063.
71. O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012; 209: 1869-1882.
72. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006; 80: 1298-1307. (Pubitemid 44904968)
73. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964. (Pubitemid 41746764)
74. Nathan C. Metchnikoff's Legacy in 2008. Nat Immunol 2008; 9: 695-698. (Pubitemid 351859148)
75. Mosser DM, EdwardsJP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
76. Mosser DM, Zhang X. Activation of murine macrophages. Curr Protoc Immunol 2008; Chapter 14: Unit 14.2.
77. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483.
78. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686. (Pubitemid 39457982)
79. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol 2008; Chapter 14: Unit 14.1.
80. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907. (Pubitemid 350231320)